Epstein Secrets

nflicting accounts. Here is what the jury missed from that tape: FBI AGENT: Tell me about the first time that Sean gave you information on a deal. ROBERT STEWART: Well, uh, I wouldn't characterize any of these as — I mean Sean would mention stuff. I don't think he had any idea that I would trade on any of th

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

nflicting accounts. Here is what the jury missed from that tape: FBI AGENT: Tell me about the first time that Sean gave you information on a deal. ROBERT STEWART: Well, uh, I wouldn't characterize any of these as — I mean Sean would mention stuff. I don't think he had any idea that I would trade on any of th

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

nflicting accounts. Here is what the jury missed from that tape: FBI AGENT: Tell me about the first time that Sean gave you information on a deal. ROBERT STEWART: Well, uh, I wouldn't characterize any of these as — I mean Sean would mention stuff. I don't think he had any idea that I would trade on any of th

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been